PET imaging could help to differentiate AD and tau pathology, but unfortunately, amyloid and tau PET were not available; therefore, we cannot exclude that our findings would have been different if a non-CBD pathology was present in our CBS patients. This evidence concerns the gene MAPT and red-green color blindness.